FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Hold Rating On Shares Of Humana Inc.

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month price target to $330 from $256, 21.5x our 2027 EPS estimate, a premium to HUM's five- and 10-year historical forward averages of 16.7x and 17.1x, respectively. We lift our 2026 EPS estimate by $0.12 to $8.83 and our 2027 EPS view by $0.30 to $15.34. We recently upgraded our 12-month fundamental outlook for the managed health care sub-industry to neutral from negative, with HUM and peers taking steps to improve profitability via increased medical premiums, strategic portfolio shifts/exits, and heightened focus on cost control within an elevated medical cost landscape. We anticipate that these actions may improve margins and profitability looking ahead to 2027-2028 and think valuations could gradually improve. However, we see 2026 as a challenging year, as guidance reflects significant earnings pressure from Star ratings headwinds, with adjusted EPS guidance of "at least $9.00," down almost 50% from $17.14 in 2025.

Related Articles

Research

Research Alert: CFRA Maintains Buy Recommendation On Shares Of Alibaba Group Holding Limited

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to USD184 from USD163, on a P/E of about 15x (unchanged) our FY 28 (Mar.) EPS of USD12.26 (based on current FX), which is within its long-term range. We trim our FY 27 EPS to CNY53.65 from CNY 56.81 but raise FY 28 to CNY83.23 from CNY74.64. We expect cloud revenue growth to accelerate from roughly 40% in the latest quarter to 47% in FY 27, fueled by AI-related revenue, which currently accounts for about 30% of the cloud business and should rise to 50% within the next year. We also expect BABA to see a meaningful profit inflection over the next several years as losses in quick commerce narrow substantially and AI-related investments become increasingly monetized. Cloud margins were just 9% this past fiscal year but should improve materially over the coming quarters, particularly as the high-margin MaaS (model-as-a-service) business scales. We continue to view BABA shares as the most compelling way to gain exposure to the AI theme in China.

$BABA
Research

Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Ccl Industries Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target by CAD4 to CAD98 on an EV/EBITDA of 11x our 2026 EBITDA forecast, a premium to its five-year average forward EV/EBITDA of 10.0x. We raise our 2026 EPS view to CAD4.90 from CAD4.89 and 2027 to CAD5.31 from CAD5.27. We maintain our Strong Buy opinion following Q1 results that beat EPS estimates. Q1 organic sales grew 3.1% with solid performance across Design, Secure, and Healthcare/Specialty segments, along with a recovery in food and beverage packaging. Although management flagged resin and aluminum inflation, we think CCL Industries is well positioned to pass through pricing. Relief from Section 232 tariffs benefited U.S. operations in Q1 and could be an additional tailwind through 2026 by reducing upward pressure on aluminum prices. The company generates consistent cash flow from operations ($37.3M in Q1 2026), allowing strategic flexibility for share repurchases and bolt-on M&A.

$CCL.B
Research

Research Alert: CFRA Lowers Rating On Shares Of Amdocs Limited To Sell From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our price target to $52 from $85, 7x our FY 26 (Sep.) EPS estimate, below DOX's three-year average (~12x) on macroeconomic uncertainty and emerging AI competition. We cut our FY 26 EPS view by $0.06 to $7.37 and lower FY 27's by $0.18 to $7.83. While Q2 results printed in line with consensus and FY 26 guidance midpoints were maintained, our primary takeaway from earnings was management's more aggressive roadmap of AI transformation, which should bring margin pressure and looks to us more like defense than offense. While 12-month-backlog growth of 2.6% was similar to recent quarters, Managed Services (65% of Q2 sales) saw growth of just 1.6%, representing a continued, steady decline from a recent peak of 4.1% in Q3 FY 25. We view this as a potential validation of AI competition fears. We expect more investments in autonomous delivery to pressure margins/cash flow, and despite some signs of early traction (five customers have signed up for aOS), sales from DOX's AI platforms remain immaterial.

$DOX